TriangleCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope… (NCT05242965)
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine trial for Lung Non-Small Cell Carcinoma (NCT05242965). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage IV non-small-cell lung cancer without progression after three to four chemoimmunotherapy cycles, including at least three with pembrolizumab. At most two maintenance cycles are allowed; targetable drivers require targeted-treatment failure or ineligibility.
The idea: STEMVAC DNA encodes five tumor proteins to stimulate immune recognition. During maintenance, patients receive randomized skin injections: STEMVAC plus sargramostim or sargramostim alone. Biopsies measure immune changes; safety is monitored.
This phase 2 study plans 40 patients. University of Washington sponsors; Nebraska Medical Center in Omaha is the sole US recruiting site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.